Related references
Note: Only part of the references are listed.Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A. Killion et al.
ENDOCRINE REVIEWS (2020)
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Aaron S. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Kentaro Kaneko et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr A. Mroz et al.
MOLECULAR METABOLISM (2019)
Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
Valerie Turcot et al.
NATURE GENETICS (2018)
Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors
Maria Buur Nordskov Gabe et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Elizabeth A. Killion et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study
Laerke S. Gasbjerg et al.
DIABETOLOGIA (2018)
A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents
Pia K. Norregaard et al.
DIABETES OBESITY & METABOLISM (2018)
GPCR desensitization: Acute and prolonged phases
Sudarshan Rajagopal et al.
CELLULAR SIGNALLING (2017)
The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor
Meena Asmar et al.
DIABETES (2017)
Reappraisal of GIP Pharmacology for Metabolic Diseases
Brian Finan et al.
TRENDS IN MOLECULAR MEDICINE (2016)
Downregulation of a GPCR by β-Arrestin2-Mediated Switch from an Endosomal to a TGN Recycling Pathway
Nazish Abdullah et al.
CELL REPORTS (2016)
Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions
Daniela Nasteska et al.
DIABETES (2014)
A Naturally Occurring GIP Receptor Variant Undergoes Enhanced Agonist-Induced Desensitization, Which Impairs GIP Control of Adipose Insulin Sensitivity
Sameer Mohammad et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Resistin Knockout Mice Exhibit Impaired Adipocyte Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Expression
Su-Jin Kim et al.
DIABETES (2013)
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture
Sonja I. Berndt et al.
NATURE GENETICS (2013)
Gipr Is Essential for Adrenocortical Steroidogenesis, However, Corticosterone Deficiency Does Not Mediate the Favorable Metabolic Phenotype of Gipr-/- Mice
Holly E. Bates et al.
DIABETES (2012)
Pleiotropic Effects of GIP on Islet Function Involve Osteopontin
Valeriya Lyssenko et al.
DIABETES (2011)
Pharmacological Characterization of Human Incretin Receptor Missense Variants
Jean-Philippe Fortin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge
Richa Saxena et al.
NATURE GENETICS (2010)
Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in mice
Rei Naitoh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet
Matthew C. Althage et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome
David P. Macfarlane et al.
JOURNAL OF ENDOCRINOLOGY (2008)
Optimized conditions for measuring lipolysis in murine primary adipocytes
Srikant Viswanadha et al.
JOURNAL OF LIPID RESEARCH (2006)
Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification
Lisa Getty-Kaushik et al.
OBESITY (2006)
FATP1 is an insulin-sensitive fatty acid transporter involved in diet-induced obesity
QW Wu et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Statistical significance for genomewide studies
JD Storey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
K Miyawaki et al.
NATURE MEDICINE (2002)